Bryon D Johnson
Overview
Explore the profile of Bryon D Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eapen M, Malec L, Armant M, Johnson B, Shi Q, Xu H, et al.
N Engl J Med
. 2025 Jan;
392(4):412-414.
PMID: 39842018
No abstract available.
2.
Quamine A, Mohrdieck N, King C, Griggs A, Kline J, Cho M, et al.
bioRxiv
. 2024 Jul;
PMID: 39026718
Background: High-risk neuroblastoma (HR-NBL) is an aggressive tumor of the sympathetic nervous system with high risk of relapse and poor overall survival. Allogeneic hematopoietic cell transplant (allo-HCT) has been used...
3.
Zurko J, Fenske T, Johnson B, Bucklan D, Szabo A, Xu H, et al.
Am J Hematol
. 2022 Sep;
97(12):1580-1588.
PMID: 36068950
We previously reported results of a first-in-human trial of bispecific LV20.19 chimeric antigen receptor T-cell (CAR-T) therapy, demonstrating high response rates in patients with relapsed, refractory (R/R) B-cell malignancies. We...
4.
Taylor M, Hillard C, Drobyski W, Szabo A, Johnson B, Zhu F, et al.
Brain Behav Immun Health
. 2022 Jun;
23:100480.
PMID: 35757656
Inflammatory physiology has been linked to behavioral and emotional symptoms in a variety of contexts and experimental paradigms. Hematopoietic cell transplantation (HCT) represents an intersection of significant immune dysregulation and...
5.
Zurko J, Xu H, Chaney K, Schneider D, Szabo A, Hari P, et al.
Cytotherapy
. 2022 May;
24(8):767-773.
PMID: 35597752
Background Aims: Selective immune pressure contributes to relapse due to target antigen downregulation in patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells. Bispecific lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T...
6.
Zurko J, Johnson B, Aschenbrenner E, Fenske T, Hamadani M, Hari P, et al.
JAMA Oncol
. 2022 Mar;
8(5):773-775.
PMID: 35266965
No abstract available.
7.
Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers C, et al.
Adv Sci (Weinh)
. 2022 Mar;
9(12):e2101267.
PMID: 35243806
Atovaquone, an FDA-approved drug for malaria, is known to inhibit mitochondrial electron transport. A recently synthesized mitochondria-targeted atovaquone increased mitochondrial accumulation and antitumor activity in vitro. Using an in situ...
8.
Mohammed A, Dashwood R, Dickinson S, Disis M, Jaffee E, Johnson B, et al.
J Cancer Prev
. 2022 Jan;
26(4):309-317.
PMID: 35047458
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the "Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents" as a virtual 2-day workshop on...
9.
Palen K, Zurko J, Johnson B, Hari P, Shah N
Cytotherapy
. 2021 Sep;
23(11):985-990.
PMID: 34538575
Background Aims: Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized outcomes for patients with relapsed/refractory B-cell malignancies. Despite the exciting results, several clinical and logistical challenges limit its wide applicability....
10.
Pan J, Chen Y, Zhang Q, Khatun A, Palen K, Xin G, et al.
Commun Biol
. 2021 Jul;
4(1):906.
PMID: 34302042
Expressed on cells of the myeloid and lymphoid lineages, V-domain Ig Suppressor of T cell Activation (VISTA) is an emerging target for cancer immunotherapy. Blocking VISTA activates both innate and...